KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) FCF Margin (2020 - 2025)

Recursion Pharmaceuticals' FCF Margin history spans 6 years, with the latest figure at 133.14% for Q4 2025.

  • For Q4 2025, FCF Margin rose 214297.0% year-over-year to 133.14%; the TTM value through Dec 2025 reached 506.52%, up 10466.0%, while the annual FY2025 figure was 506.52%, 10466.0% up from the prior year.
  • FCF Margin reached 133.14% in Q4 2025 per RXRX's latest filing, up from 2363.71% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 1369.96% in Q1 2022 to a low of 2704.07% in Q4 2021.
  • Average FCF Margin over 5 years is 866.55%, with a median of 699.26% recorded in 2023.
  • The largest YoY upside for FCF Margin was 2960705bps in 2021 against a maximum downside of -280752bps in 2021.
  • A 5-year view of FCF Margin shows it stood at 2704.07% in 2021, then surged by 79bps to 575.56% in 2022, then dropped by -21bps to 699.15% in 2023, then plummeted by -226bps to 2276.11% in 2024, then skyrocketed by 94bps to 133.14% in 2025.
  • Per Business Quant, the three most recent readings for RXRX's FCF Margin are 133.14% (Q4 2025), 2363.71% (Q3 2025), and 392.94% (Q2 2025).